WO2013110856A1 - A drug delivery system - Google Patents

A drug delivery system Download PDF

Info

Publication number
WO2013110856A1
WO2013110856A1 PCT/FI2013/050068 FI2013050068W WO2013110856A1 WO 2013110856 A1 WO2013110856 A1 WO 2013110856A1 FI 2013050068 W FI2013050068 W FI 2013050068W WO 2013110856 A1 WO2013110856 A1 WO 2013110856A1
Authority
WO
WIPO (PCT)
Prior art keywords
core
membrane
delivery system
drug
release
Prior art date
Application number
PCT/FI2013/050068
Other languages
English (en)
French (fr)
Inventor
Heikki Lyytikäinen
Harri Jukarainen
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013110856(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US14/371,848 priority Critical patent/US10500381B2/en
Priority to RS20181218A priority patent/RS57911B1/sr
Priority to CN201380006458.1A priority patent/CN104144702B/zh
Priority to EA201400834A priority patent/EA032208B1/ru
Priority to BR112014017834-8A priority patent/BR112014017834B1/pt
Priority to SI201331216T priority patent/SI2806893T1/sl
Priority to SG11201404032SA priority patent/SG11201404032SA/en
Priority to NZ627461A priority patent/NZ627461A/en
Priority to KR1020147023356A priority patent/KR102004014B1/ko
Priority to UAA201409275A priority patent/UA116197C2/uk
Priority to EP13702817.1A priority patent/EP2806893B1/en
Priority to JP2014552669A priority patent/JP6236401B2/ja
Priority to MX2014008906A priority patent/MX355961B/es
Application filed by Bayer Oy filed Critical Bayer Oy
Priority to LTEP13702817.1T priority patent/LT2806893T/lt
Priority to CU2014000094A priority patent/CU24431B1/es
Priority to DK13702817.1T priority patent/DK2806893T3/en
Priority to CA2861947A priority patent/CA2861947A1/en
Priority to PL13702817T priority patent/PL2806893T3/pl
Priority to AU2013213514A priority patent/AU2013213514B2/en
Priority to ES13702817.1T priority patent/ES2691635T3/es
Publication of WO2013110856A1 publication Critical patent/WO2013110856A1/en
Priority to IL233599A priority patent/IL233599B/en
Priority to PH12014501654A priority patent/PH12014501654B1/en
Priority to CR20140358A priority patent/CR20140358A/es
Priority to ZA2014/06206A priority patent/ZA201406206B/en
Priority to HK15104265.3A priority patent/HK1203802A1/xx
Priority to HRP20181707TT priority patent/HRP20181707T1/hr
Priority to CY181101075T priority patent/CY1120773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • a drug delivery system A drug delivery system
  • the present invention provides a novel drug delivery system for the controlled release of therapeutically active substances at a predetermined, essentially constant release rate over a prolonged period of time.
  • the delivery system comprises at least one core comprising said therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of a substantially inert material, wherein the intermediary layer is applied between the core and the membrane or between two membrane layers.
  • Diffusion controlled systems can typically be divided into reservoir, matrix and hybrid devices.
  • Reservoir drug delivery devices have a polymer membrane encasing the active agent.
  • the active agent can be in the solid or in the liquid state, and the membrane can be
  • the active substance diffuses through the membrane at a controllable rate.
  • the release rate of the drug will be constant versus time until exhaustion of the active substance excess.
  • the saturated state would be difficult to maintain for drugs having low fluid solubility. Further, although the requirements for constant release would be met, the release will generally not be constant in the initial and end period. When the system is placed in a release medium, it takes a certain time for the system to reach a steady state and either a lag time or an initial burst is observed. If the membrane does not contain drug molecules at the time of placement, an induction period will be needed to saturate the membrane. Burst release is often observed in reservoir systems stored for some time prior to use. During storage the agent saturates the entire membrane. When placed in a release medium, the agent that has diffused to the surface of the membrane is released immediately, causing a burst effect. Also dose dumping due to minor flaws in the coating can lead to burst release even prior to patient administration.
  • the concentration of the dissolved drug in the core will decrease below the saturation point and as a result the release rate will decrease.
  • the drug is dissolved or dispersed in a polymer matrix.
  • the release rate is often proportional to the square root of elapsed time.
  • the release behavior of these systems is dependent on the physical properties of the drug, drug load, particle size, solubility of the drug in the polymer and diffusivity in the polymer matrix.
  • the shape of the device, surface area and the path length of diffusion are also important parameters. With these systems the release rate will decrease with time as a result of increasing path length for the drug solutes to diffuse from the center of the device to the surface.
  • One proposed method to improve the consistency of release is to use systems with uneven initial drug distributions, with higher loading concentrations towards the center of the device (Lee, Polymer 25 (1984), pp. 973-978).
  • the active substance is homogeneously dispersed in the polymer matrix, which is covered by a rate limiting membrane.
  • Drug release is controlled by both the polymer membrane and the matrix. Drug dissolves first into the core polymer, dissolved drug travels by diffusion towards the inner surface of the membrane, dissolves in the membrane, diffuses through the membrane to the outer surface of the membrane and dissociates finally into the surrounding media.
  • the release rate can be accurately adjusted with this system, but initial burst can take place and toward the end of the release period the release rate commonly decreases.
  • Burst release may be the optimal mechanism of delivery in rare instances, but is often problematic because it is unpredictable and, even when the burst is desired, the amount of burst cannot be significantly controlled.
  • the initial high release rates may lead to drug concentrations near or above the toxic level in vivo. Any drug released during the burst stage may also be metabolized and excreted without being effectively utilized. Even if no harm is done during the burst release, this amount of drug is essentially wasted, and the ineffective drug usage may have therapeutic and economic effects.
  • the traditional way to adjust the release rate of a drug substance in a polymer based delivery system has been to change different parameters, such as the area of the device, the thickness of the membrane; the drug load in the core, the core and membrane material, end capping the device or incorporating fillers into the polymer composition of the membrane.
  • the predetermined release rate should also remain as constant as possible during the whole life-span of the device. This would be important to maintain the daily dosage of the drug in a therapeutically effective window long enough, and still lower the total amount of drug administered to the patient. It would also enable reasonably low drug load in the device so that the disposal of the device after the treatment period would be less problematic and would satisfy environmental requirements.
  • US 5,660,848 discloses an implantable drug delivery device comprising a matrix core, an outer layer, and an intermediate layer between the core and the outer layer.
  • the intermediate layer is made of porous polymeric material, preferably cellulose or regenerated cellulose.
  • WO 03/017971 discloses an embodiment wherein a drug delivery system comprises a core and two elastomer membrane layers of different thickness for controlling the release rate of active agents.
  • the elastomer membrane is preferably a siloxane-based elas- tomer, such as poly(dimethylsiloxane) (PDMS) or poly(ethylene oxide)-PDMS.
  • PDMS poly(dimethylsiloxane)
  • PDMS poly(ethylene oxide)-PDMS.
  • drug formulations for sublingual and subcutaneous administration of insulin are disclosed.
  • the formulation may be in the form of a film comprising a bottom layer and a top layer which surround a core layer containing the active agent.
  • the object of the present invention is to provide a novel drug delivery system for the con- trolled release of at least one therapeutically active substance at a predetermined, essentially constant release rate over a prolonged period of time.
  • the delivery system comprises at least one core comprising said therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of an inert material applied between the core and the membrane or between two membranes.
  • the intermediary layer is capable of preventing direct contact between the core and the membrane or between two membrane layers but is not covalently bound to any of them.
  • said intermediary layer comprises particulate matter, particles, granules, crystals, micro- or nanoscaled crystals or powder in a solid, suspended or gel form.
  • a further object of the invention is to provide a drug delivery system having no or only minimal initial burst.
  • Figure 1 is a schematic view of a delivery system comprising a core 1 comprising a therapeutically active agent, a membrane 2 and an intermediary layer 3 comprising inert parti- cles and applied between the outer surface of the core 1 and the inner surface of a membrane layer.
  • Figure 2 illustrates an example of the release rates.
  • First release profile has been derived for a prior art core encased by a membrane (rodges), the second release profile for a core the surface of which has been covered by silicon oil (squares) and the third release profile for a core covered by silica particles and then encased by a membrane (circles).
  • the samples have been manufactured by coating extrusion and the ends of the samples have been sealed.
  • Figure 3 illustrates another example of the release rates.
  • First release profile has been derived for a prior art core encased by a membrane (rodges), the second release profile for a core the surface of which has been covered by silica particles (squares) and the third release profile for a core covered by silica particles and then encased by a membrane (cir- cles).
  • the samples have been manufactured by coating extrusion and the ends of the samples have been sealed.
  • Figure 4 illustrates a further example of the release rates.
  • First release profile has been derived for a prior art core comprising levonorgestrel and encased by a membrane (cir- cles), and the second release profile for a core comprising levonorgestrel, wherein the surface of the core has been coated by talcum particles and the whole system has been encased by a membrane (squares).
  • the samples have been manufactured by coating extrusion and the ends of the samples have been sealed.
  • the release profile has been calculated from the data of the accelerated release test of levonorgestrel at 60° C and corresponds to the release rate of 5 years.
  • the drug delivery system comprising at least one core comprising therapeutically active substance(s), at least one membrane encasing the core and an intermediary layer of a substantially inert material applied between the core and the membrane or between two membrane layers.
  • the intermediary layer is capable of preventing direct contact between the core and the membrane or between two membranes but is not covalently bound to either of them.
  • said intermediary layer comprises particulate matter, particles, granules, crystals, micro- or nanoscaled crystals or powder in a solid, suspended or gel form.
  • the drug delivery system consists of one core comprising at least one therapeutically active substance, an intermediary layer ap- plied on the surface of the core, and a membrane encasing the core and the intermediary layer.
  • the drug delivery system consists of at least two cores, at least one of the cores comprising a therapeutically active substance, an intermediary layer applied on the surface of at least the core(s) comprising the active substance, and a membrane encasing the cores and the intermediary layer(s).
  • the drug delivery system consists of one core comprising at least one therapeutically active substance, a membrane encasing the core, an outer membrane encasing the core-membrane system and an intermediary layer applied between said membrane and outer membrane.
  • the system can take a wide variety of shapes and forms for administering the therapeutically active agent at controlled rate to different areas of the body.
  • the invention can be applied to any type of formulation as long as it comprises a core containing the therapeutically active agent, at least one membrane and an intermediary layer controlling the release of a therapeutically active agent.
  • the delivery system may for example have a form of an implant, an intrauterine system (IUS), an intracervical device (ICD), a vaginal ring, a helical coil or a spring and a like.
  • the intermediary layer comprises a suitable inert material applied between the outer surface of the core and the inner surface of the membrane or when there are two or more membranes, between two membrane layers.
  • inert or “substantially inert” means here a material which is not covalently bound to the core or membrane material and is not a polymer membrane.
  • the intermediary layer prevents or at least decreases the direct contact between the core(s) and the membrane(s) and creates an additional diffusion layer with two interfaces forming between the core(s) and the mem- brane or between two membranes. The diffusion will not take place until the intermediary layer gets wet, for example when the external body fluid is absorbed through the membrane ⁇ ) in the target organ. For this reason the drug substance cannot migrate from the core to the membrane layer(s) during storage. This will eliminate or diminish initial burst and will further help to adjust the release rate of the therapeutically active substance.
  • Exemplary inert material or combination of materials comprising particulate matter, particles, granules, crystals, micro- or nanoscaled crystals or powder in a solid, suspended or gel form that can in practice be used as an intermediary layer in the drug delivery system according to the present invention include inorganic salts, e.g. calcium sulphate, magnesi- urn sulphate, sodium carbonate, calcium carbonate and barium sulphate, organic salts such as sodium lactate and other organic compounds such as saccharides, e.g.
  • mono-and polysaccharides such as starch, methyl cellulose, croscarmellose sodium, microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, dextrin, lactose, sucrose, fructose, trehalose, sugar alcohols, polyols and crystalline sugars, mannitol, sorbitol, xyli- tol, carboxymethylcellulose and salts thereof, organic non saccharides, e.g.
  • the material is non-swellable or only slightly swellable in biological fluids.
  • the substantially inert material is selected from the group consisting of silica, fumed and precipitated silica and talc.
  • the core of the delivery system consists essentially of a polymer composition, that is, the core is a polymer matrix wherein the therapeutically active substance or substances are dissolved or dispersed.
  • the polymer composition of the core is permeable to the therapeutically active substance.
  • the core(s) may be solid or hollow. Hollow cores can be easily assembled for example on the body of an intrauterine system. In addition, by using hollow cores a continuous cavity formed inside a vaginal ring reduces the overall weight of the device and influences beneficially the elasticity, flexibility and softness of the ring which all may give better wearing comfort for the user.
  • the cores may also comprise a support member consisting of an inert material, for example a polymer rod or a metal wire, to modify the elasticity or flexibility of the core.
  • the delivery system of the present invention can also be applied for example on the surface of a medical device, such as a stent or a catheter.
  • the delivery system consists of two or more cores
  • said cores are preferably positioned next to each other.
  • the length of the compartments may be same or different.
  • the cores may or may not be separated from each other by a separation membrane or by an inert placebo core.
  • the membrane comprises a polymer composition which is permeable to the therapeutically active substance but preferably less permeable than the polymer composition of the core.
  • the membrane may cover only a part of the delivery system, it advantageously encases the whole delivery system.
  • the thickness of the membrane depends on materials and active agents used as well as on the desired release profiles, but generally the thickness is smaller than the thickness of the core member.
  • the membrane may consist of more than one layer, in which case each layer has a certain thickness, and the thickness of the layers may be the same or different.
  • Polymer compositions of the core, the membrane and the possible separation membrane or the inert placebo compartment can be the same or different and may stand for one single polymer, a mixture of polymers or the polymer composition may be made up of polymers that are blended with each other.
  • any polymer either biodegradable or non-biodegradable, can be used as long as it is biocompatible.
  • Polysiloxanes in particular poly (dimethyl siloxane) (PDMS) and modified poly (dimethyl siloxanes), are highly suitable for use as a membrane or core material.
  • suitable materials include, but are not limited to, copolymers of dimethylsiloxanes and methylvinylsiloxanes, ethylene/vinyl acetate copolymers (EVA), polyethylene, polypropylene, ethylene/propylene copolymers, acrylic acid polymers, eth- ylene/ethyl acrylate copolymers, polytetrafluoroethylene (PTFE), polyurethanes, thermoplastic polyurethanes, polyurethane elastomers, polybutadiene, polyisoprene,
  • EVA ethylene/vinyl acetate copolymers
  • PTFE polytetrafluoroethylene
  • PTFE polyurethanes
  • thermoplastic polyurethanes polyurethane elastomers
  • polybutadiene polyisoprene
  • HEMA polyvinyl chloride, polyvinyl acetate, polyethers, polyacrylonitriles, polyethylene glycols, polymethylpentene, polybutadiene, polyhydroxy alkanoates, poly(lactic acid), poly(glycolic acid), polyanhydrides, polyorthoesters, hydrophilic polymers such as the hydrophilic hydrogels , cross-linked polyvinyl alcohol, neoprene rubber, butyl rubber, hydroxyl-terminated organopolysiloxanes of the room temperature vulcanizing type which harden to elastomers at room temperature following the addition of cross-linking agents in the presence of curing catalysts, one- or two-component dimethylpolysiloxane compositions cured by hydro silylation at room temperature or under elevated temperatures, as well as mixtures thereof.
  • hydrophilic polymers such as the hydrophilic hydrogels , cross-linked polyvinyl alcohol, neoprene rubber, butyl rubber, hydroxy
  • the structural integrity of the material may be enhanced by the addition of filler such as silica or diatomaceous earth.
  • filler such as silica or diatomaceous earth.
  • the polymers can also be mixed with other additives, for example to adjust their hydrophilic or hydrophobic proper- ties, while taking into account that all additives need to be biocompatible and harmless to the patient.
  • the core or membrane may also comprise additional material to further adjust the release rate of one or several of the therapeutic substances.
  • additional material for example such as tensides, anti-foaming agents, solubilisers or absorption retarders, or a mixture of any two or more of such substances, can also be added in order to impart the desired physical properties to the body of the delivery system.
  • additives such as pigments, glossing agents, matting agents, colorants, mica or equal can be added to the body of the delivery system or the membrane or to both in order to provide the delivery system with a desired visual appearance.
  • the amount of the therapeutically active agent incorporated in the delivery system varies depending on the particular therapeutically active agent, intended use of the substance, expected release rate and the time for which the system is expected to provide therapy. Since a variety of devices with varying sizes can be formulated for administering dosages, there is no critical upper limit on the amount of therapeutically active agent incorporated in the device.
  • the lower limit depends on the activity of the therapeutically active agent and the ex- pected release time. A person skilled in the art is readily able to determine the amount of the therapeutically active agent needed for each specific application of the delivery system.
  • the amount of a therapeutically active agent in the delivery system varies be- tween almost zero to 60 wt-%, when it is mixed into the polymer, the preferred amount being between 10-40 wt-% of the weight of the delivery system.
  • Other possible ranges of the amount of the therapeutically active agent are 0.5-60 wt-%, 5-55 wt-%, 10-45 wt-%, 25-60 wt-%, 40-50 wt-% and 15-35 wt-%. Since the release rate is relatively constant during the whole time of usage, a lower amount of drug will be often sufficient to achieve necessary period of administration as compared to the traditional delivery systems, where the drug load is partly consumed by initial burst.
  • the daily dosage of the therapeutically active substances for a defined condition to be treated and for a defined substance can be achieved with the delivery system according to the invention particularly by varying the polymer composition of the core or membrane or both and by varying the material of the intermediary layer, the amount and/or the properties of the layer, for example thickness, size and crystal form of the particles etc.
  • the particle size is below 300 microns, preferably from 5 to 250 mi- crons or from 20 to 200 microns.
  • other parameters such as the size and form of the device and the drug load will influence the daily dose released from said device. Some, but not undue, experimentation will be needed to find the most suitable parameters for each combination.
  • the expected practical life-time of the device varies from one week to several years, for example from one year to 7 years, preferably from 1 year to 5 years, or from one week to 12 months, preferably from one week to 6 months and more preferably from 21 days to 3 months.
  • the drug delivery system according to this invention can be manufactured by any technique known in the art.
  • the therapeutically active agent may be mixed within the core material, processed to the desired shape by moulding, injection moulding, rotation/ injection moulding, casting, extrusion, such as co-extrusion, coating extrusion, sequential extrusion and/or blend-extrusion or other appropriate methods.
  • the intermediary layer can be produced by encasing, coating, dusting or smoothing the surface of the core or the membrane by the inert material.
  • granules, particles, crystals, microcrystals, powder or suspension of an inert material can be adhered on the sticky or gummy surface of the core, the core or a part of it can be sprayed with the mate- rial or with a suspension of said material in a suitable solvent, the core can be dipped in such a suspension, or the surface of the core can be wetted by a suitable liquid, for example a solvent or silicone oil and then the core is dipped in the inert material, finally by letting the solvent, if any, to evaporate.
  • the inert solid material can be mixed or suspended in a carrier material known in the art, for example silicone oil or hard fat or other encapsulation material, which is then applied on the surface of the core.
  • the membrane layer can be applied on the core and on the intermediary layer according to known methods, for example by mechanical stretching or expanding a prefabricated, tube formed membrane by using pressurised gas like air or by swelling in a suitable solvent like cyclohexane, diglyme, propanol, isopropanol or a mixture of solvents, or preferably by extrusion, moulding, spraying or dipping.
  • the ends of the drug delivery system can be combined by known methods to produce a vaginal delivery device.
  • the delivery system is intended to be in the form of rod or a medicated capsule, e.g. an implant or an intrauterine system
  • the ends of the core-membrane rod can be sealed during the extrusion process or by using an adhesive.
  • a core comprising an intermediary layer and a core comprising an intermediary layer and a membrane were made and the results were compared to a corresponding core with a membrane but without any in- termediary layer.
  • the samples have been manufactured by coating extrusion and the ends of the samples have been sealed.
  • the content of the therapeutically active agent in the core is 50 wt-% (weight percent), and the agent was mixed in the elastomer with a mixer before extrusion.
  • the diameter of the cores used in experiments is 2.0 mm and the length is 20 mm.
  • the thickness of the membrane is 0.3 mm.
  • the samples comprising the intermediary layer have lower initial dose and lower daily dose over a relatively long period of time, and the decrease is more enhanced with the samples comprising both an intermediary layer and a membrane encasing the core and said intermediary layer. Further, as can be seen in Figures 2-4 the samples comprising the intermediary layer and the membrane have surprisingly constant release rate of the active drug substance as compared to the reference samples.
  • the core was treated with a thin layer of silicon oil and covered by a talcum layer.
  • the membrane material prepared according to example 1 was coating extruded on the core.
  • the wall thickness of the resulting membrane was 0.3 mm.
  • the tube-like reservoir was swollen in cyclohexane and assembled on the vertical stem of a T-shaped IUS body. Cyclohexane was allowed to evaporate. The ends of the reservoir were sealed by using silicone glue.
  • An adhesive (Nusil Med 1-4213) is spread on the other end of the coupling means and polyethylene rod is pushed approximately 5 mm into the core.
  • the cross sectional surfaces of the core-membrane tube and the other end of the coupling means are dabbed with the same adhesive and the other end of the core-membrane system is pushed over the polyethylene rod so that the ends of the core-membrane system meet each other.
  • the adhesive is cured at 100 °C for 1 hour.
  • the release rate of the drug from the implant was measured in vitro as follows:
  • the intrauterine delivery systems were attached into a stainless steel holder in vertical position and the holders with the devices were placed into glass bottles containing 250 ml of a dissolution medium.
  • the glass bottles were shaken in shaking water bath 100 rpm at 37 °C.
  • the dissolution medium was withdrawn and replaced by a fresh dissolution medium at predetermined time intervals, and the amount of the released drug was analysed by using standard HPLC methods.
  • the concentration of the dissolution medium and the moment of change (withdrawal and replacement) of medium were selected so that sink- conditions were maintained during the test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)
PCT/FI2013/050068 2012-01-23 2013-01-22 A drug delivery system WO2013110856A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES13702817.1T ES2691635T3 (es) 2012-01-23 2013-01-22 Un sistema para el suministro de un fármaco
CU2014000094A CU24431B1 (es) 2012-01-23 2013-01-22 Sistema para la administración de fármacos
LTEP13702817.1T LT2806893T (lt) 2012-01-23 2013-01-22 Vaisto pristatymo sistema
EA201400834A EA032208B1 (ru) 2012-01-23 2013-01-22 Система доставки лекарств
RS20181218A RS57911B1 (sr) 2012-01-23 2013-01-22 Sistem za isporuku lekova
SI201331216T SI2806893T1 (sl) 2012-01-23 2013-01-22 Sistem za dovajanje zdravil
SG11201404032SA SG11201404032SA (en) 2012-01-23 2013-01-22 A drug delivery system
NZ627461A NZ627461A (en) 2012-01-23 2013-01-22 A drug delivery system with a core/membrane structure which contains an intermediary layer between core and membrane to reduce initial burst
KR1020147023356A KR102004014B1 (ko) 2012-01-23 2013-01-22 약물 전달 시스템
UAA201409275A UA116197C2 (uk) 2012-01-23 2013-01-22 Система доставлення ліків
EP13702817.1A EP2806893B1 (en) 2012-01-23 2013-01-22 A drug delivery system
DK13702817.1T DK2806893T3 (en) 2012-01-23 2013-01-22 drug delivery
MX2014008906A MX355961B (es) 2012-01-23 2013-01-22 Sistema para la administracion de farmacos.
US14/371,848 US10500381B2 (en) 2012-01-23 2013-01-22 Drug delivery system
CN201380006458.1A CN104144702B (zh) 2012-01-23 2013-01-22 药物递送系统
BR112014017834-8A BR112014017834B1 (pt) 2012-01-23 2013-01-22 sistema de distribuição de fármacos
JP2014552669A JP6236401B2 (ja) 2012-01-23 2013-01-22 薬剤送達システム
CA2861947A CA2861947A1 (en) 2012-01-23 2013-01-22 A drug delivery system
PL13702817T PL2806893T3 (pl) 2012-01-23 2013-01-22 System dostarczania leków
AU2013213514A AU2013213514B2 (en) 2012-01-23 2013-01-22 A drug delivery system
IL233599A IL233599B (en) 2012-01-23 2014-07-10 drug delivery system
PH12014501654A PH12014501654B1 (en) 2012-01-23 2014-07-18 A drug delivery system
CR20140358A CR20140358A (es) 2012-01-23 2014-07-23 Sistema para la administración de fármacos
ZA2014/06206A ZA201406206B (en) 2012-01-23 2014-08-22 A drug delivery system
HK15104265.3A HK1203802A1 (en) 2012-01-23 2015-05-05 A drug delivery system
HRP20181707TT HRP20181707T1 (hr) 2012-01-23 2018-10-17 Sustav za isporuku lijeka
CY181101075T CY1120773T1 (el) 2012-01-23 2018-10-18 Ενα συστημα παροχης φαρμακου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20125069 2012-01-23
FI20125069 2012-01-23

Publications (1)

Publication Number Publication Date
WO2013110856A1 true WO2013110856A1 (en) 2013-08-01

Family

ID=47666152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2013/050068 WO2013110856A1 (en) 2012-01-23 2013-01-22 A drug delivery system

Country Status (39)

Country Link
US (1) US10500381B2 (hr)
EP (1) EP2806893B1 (hr)
JP (1) JP6236401B2 (hr)
KR (1) KR102004014B1 (hr)
CN (1) CN104144702B (hr)
AR (1) AR089765A1 (hr)
AU (1) AU2013213514B2 (hr)
BR (1) BR112014017834B1 (hr)
CA (1) CA2861947A1 (hr)
CL (1) CL2014001935A1 (hr)
CO (1) CO7020911A2 (hr)
CR (1) CR20140358A (hr)
CU (1) CU24431B1 (hr)
CY (1) CY1120773T1 (hr)
DK (1) DK2806893T3 (hr)
DO (1) DOP2014000171A (hr)
EA (1) EA032208B1 (hr)
EC (1) ECSP14010605A (hr)
ES (1) ES2691635T3 (hr)
HK (1) HK1203802A1 (hr)
HR (1) HRP20181707T1 (hr)
IL (1) IL233599B (hr)
LT (1) LT2806893T (hr)
MX (1) MX355961B (hr)
MY (1) MY172812A (hr)
NZ (1) NZ627461A (hr)
PE (1) PE20141818A1 (hr)
PH (1) PH12014501654B1 (hr)
PL (1) PL2806893T3 (hr)
PT (1) PT2806893T (hr)
RS (1) RS57911B1 (hr)
SG (1) SG11201404032SA (hr)
SI (1) SI2806893T1 (hr)
TR (1) TR201815247T4 (hr)
TW (1) TWI626951B (hr)
UA (1) UA116197C2 (hr)
UY (1) UY34583A (hr)
WO (1) WO2013110856A1 (hr)
ZA (1) ZA201406206B (hr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392454A (zh) * 2014-06-28 2016-03-09 安德罗玛克实验室股份有限公司 用于预防早产的含有延长、不变和持续释放的孕酮的环扎子宫托
WO2018202574A1 (en) 2017-05-04 2018-11-08 Bayer Oy Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception
WO2019063382A1 (en) * 2017-09-27 2019-04-04 Bayer Oy METHOD FOR MODIFYING THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX
CN109954198A (zh) * 2017-12-25 2019-07-02 先健科技(深圳)有限公司 药物球囊及其制备方法
WO2020172065A1 (en) * 2019-02-19 2020-08-27 Particle Sciences Inc. Compartmentalized drug delivery devices
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
RU2780242C2 (ru) * 2017-09-27 2022-09-21 Байер Ою Способ модифицированного высвобождения терапевтически активного средства из эластомерного матрикса

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200276110A1 (en) * 2015-12-21 2020-09-03 Bayer Oy A method of manufacturing a vaginal ring

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
WO2003017971A1 (en) 2001-08-31 2003-03-06 Schering Oy Drug delivery system
US20050214251A1 (en) 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
WO2008061963A2 (en) * 2006-11-20 2008-05-29 N.V. Organon Helically-shaped drug delivery system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3879031T2 (de) * 1987-08-08 1993-06-24 Akzo Nv Kontrazeptives implantat.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
AU2001258442A1 (en) 2000-05-10 2001-11-20 Leiras Oy Drug delivery device, especially for the delivery of levonorgestrel
DE10209979A1 (de) 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
ATE372772T1 (de) 2004-07-13 2007-09-15 Schering Oy Retardiertes freigabesystem mit kontrollierter initialabgabe
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
AU2006213439A1 (en) 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US8137327B2 (en) 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
FI121000B (fi) 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
EP2658524A1 (en) * 2010-12-27 2013-11-06 Dow Corning Corporation Drug delivery dispersion and film formed therefrom

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
WO2003017971A1 (en) 2001-08-31 2003-03-06 Schering Oy Drug delivery system
US20050214251A1 (en) 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
WO2008061963A2 (en) * 2006-11-20 2008-05-29 N.V. Organon Helically-shaped drug delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, POLYMER, vol. 25, 1984, pages 973 - 978
XIAO HUANG; CHRISTOPHER S BRAZEL, JOURNAL OF CONTROLLED RELEASE, vol. 73, no. 2-3, 2001, pages 121 - 136

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
CN105392454A (zh) * 2014-06-28 2016-03-09 安德罗玛克实验室股份有限公司 用于预防早产的含有延长、不变和持续释放的孕酮的环扎子宫托
WO2018202574A1 (en) 2017-05-04 2018-11-08 Bayer Oy Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception
WO2019063382A1 (en) * 2017-09-27 2019-04-04 Bayer Oy METHOD FOR MODIFYING THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX
RU2780242C2 (ru) * 2017-09-27 2022-09-21 Байер Ою Способ модифицированного высвобождения терапевтически активного средства из эластомерного матрикса
US11666552B2 (en) 2017-09-27 2023-06-06 Bayer Oy Method for modifying release of a therapeutically active agent from an elastomeric matrix
CN109954198A (zh) * 2017-12-25 2019-07-02 先健科技(深圳)有限公司 药物球囊及其制备方法
CN109954198B (zh) * 2017-12-25 2021-10-12 先健科技(深圳)有限公司 药物球囊及其制备方法
WO2020172065A1 (en) * 2019-02-19 2020-08-27 Particle Sciences Inc. Compartmentalized drug delivery devices

Also Published As

Publication number Publication date
SI2806893T1 (sl) 2019-02-28
US10500381B2 (en) 2019-12-10
US20140350488A1 (en) 2014-11-27
AR089765A1 (es) 2014-09-17
MX355961B (es) 2018-05-07
IL233599B (en) 2019-07-31
ZA201406206B (en) 2019-06-26
CU20140094A7 (es) 2014-11-27
EA201400834A1 (ru) 2014-12-30
LT2806893T (lt) 2018-12-10
UY34583A (es) 2013-09-02
CL2014001935A1 (es) 2015-04-10
PT2806893T (pt) 2018-11-09
EP2806893B1 (en) 2018-07-18
CN104144702A (zh) 2014-11-12
CR20140358A (es) 2014-11-17
AU2013213514B2 (en) 2017-07-13
EA032208B1 (ru) 2019-04-30
TR201815247T4 (tr) 2018-11-21
CU24431B1 (es) 2019-07-04
EP2806893A1 (en) 2014-12-03
DK2806893T3 (en) 2018-11-05
HRP20181707T1 (hr) 2019-02-22
AU2013213514A1 (en) 2014-08-07
PH12014501654A1 (en) 2014-10-13
UA116197C2 (uk) 2018-02-26
CY1120773T1 (el) 2019-12-11
CA2861947A1 (en) 2013-08-01
CN104144702B (zh) 2018-03-06
BR112014017834A2 (hr) 2017-06-20
ECSP14010605A (es) 2015-12-31
CO7020911A2 (es) 2014-08-11
PE20141818A1 (es) 2014-12-18
PH12014501654B1 (en) 2014-10-13
HK1203802A1 (en) 2015-11-06
BR112014017834A8 (pt) 2017-07-11
PL2806893T3 (pl) 2019-01-31
BR112014017834B1 (pt) 2021-05-18
MX2014008906A (es) 2014-08-26
NZ627461A (en) 2016-07-29
JP2015504083A (ja) 2015-02-05
RS57911B1 (sr) 2019-01-31
MY172812A (en) 2019-12-12
ES2691635T3 (es) 2018-11-28
IL233599A0 (en) 2014-08-31
TWI626951B (zh) 2018-06-21
SG11201404032SA (en) 2014-08-28
KR20140127262A (ko) 2014-11-03
DOP2014000171A (es) 2014-08-15
JP6236401B2 (ja) 2017-11-22
TW201343204A (zh) 2013-11-01
KR102004014B1 (ko) 2019-07-25

Similar Documents

Publication Publication Date Title
EP2806893B1 (en) A drug delivery system
Mashak et al. Silicone polymers in controlled drug delivery systems: a review
JP4881861B2 (ja) デリバリーシステム
US20120238994A1 (en) Two-piece injectable drug delivery device with heat-cured seal
CN106075698B (zh) 药物释放医用导管、管和装置
JPH10513471A (ja) 鎮痛薬投与のための方法と装置
JP2009019038A (ja) 非ポリマー持続性解離供給システム
US20150342894A1 (en) Drug delivery systems and related methods of use
CA2927750A1 (en) Intrauterine delivery system
AU2007324467A1 (en) Vaginal delivery system for mirtazapine
JPH11503138A (ja) リスペリドンの速度調節された経皮投与
JP7103725B2 (ja) 植え込み型メディカメントデリバリーシステム
MXPA00001941A (en) Sustained release drug delivery devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13702817

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 233599

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14371848

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013702817

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014552669

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2861947

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12014501654

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 001141-2014

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/008906

Country of ref document: MX

Ref document number: CR2014-000358

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2014001935

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2013213514

Country of ref document: AU

Date of ref document: 20130122

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147023356

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201409275

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201400834

Country of ref document: EA

Ref document number: IDP00201405012

Country of ref document: ID

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014017834

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014017834

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140721